A few years ago, most people had never heard of GLP-1.
Today, these medications are being studied not only for obesity, but also for cardiovascular disease, kidney disease, liver disease, sleep apnea, heart failure, reproductive health, addiction, and neurological conditions.
So are they simply weight-loss drugs, or are they becoming something much bigger?
GLP-1 stands for glucagon-like peptide-1, a gut hormone that helps regulate appetite, blood glucose, digestion, and metabolic signaling. GLP-1 medications work by activating this pathway. These days, they have become almost synonymous with weight loss.
And that makes sense. Drugs such as semaglutide and tirzepatide can substantially reduce appetite and help many people lose weight. But the conversation is shifting, especially for patients, healthcare professionals, and anyone curious about what these drugs may do beyond changing the number on the scale.
Researchers are now exploring how these medications may affect the heart, kidneys, liver, sleep, reproductive health, brain, and even addictive behaviors. Some of these benefits are no longer just theories. They are supported by large clinical trials and, in some cases, new regulatory approvals.
Others are still in their early stages or have not produced the clinical results researchers hoped for.
This distinction matters because GLP-1 medications are being prescribed not only for weight management, but also to improve outcomes in several diseases. However, the strength of evidence varies considerably.
A medication can improve a laboratory marker without helping someone live longer, feel better, or experience fewer symptoms.
So instead of asking:
“What else can GLP-1 drugs do?”
It is more useful to ask:
“Which effects are supported by solid human evidence, which may be largely explained by weight loss, and which are still uncertain?”
This article explores how GLP-1 medications work, what clinical trials show about cardiovascular disease, diabetic kidney disease, MASH, sleep apnea, heart failure, PCOS, alcohol use disorder, and brain diseases, as well as the side effects and nutritional considerations that deserve attention.
Key takeaways
- GLP-1 receptor agonists influence appetite, blood glucose, digestion, and several metabolic pathways.
- The strongest evidence beyond weight loss involves cardiovascular disease, diabetic kidney disease, MASH, obesity-related sleep apnea, and certain forms of heart failure.
- Tirzepatide often appears in GLP-1 discussions, but it activates both GLP-1 and GIP receptors.
- Benefits in PCOS and alcohol use disorder appear promising, but the evidence is not yet strong enough for broad treatment claims.
- Large Alzheimer’s and Parkinson’s trials have not shown that GLP-1 medications slow disease progression.
- “Beyond weight loss” does not always mean “independent of weight loss.”
- These are prescription medications with real side effects, nutritional considerations, and monitoring needs.
What GLP-1 medications actually do
GLP-1 stands for glucagon-like peptide-1. It is a hormone released by the gut after eating to help manage blood glucose and signal fullness to the brain.
But its role extends beyond appetite. This helps explain why researchers are now interested in much more than weight loss.
GLP-1 prompts the pancreas to release insulin when blood glucose is elevated, slows the rate at which the stomach empties, reduces glucagon, which otherwise encourages the liver to release glucose, and communicates with brain regions involved in appetite and reward.
Natural GLP-1 does not remain active for long. Medications such as semaglutide, liraglutide, and dulaglutide are designed to activate the same receptor for much longer, helping treat type 2 diabetes and obesity.
Tirzepatide is slightly different. It activates both GLP-1 and GIP, or glucose-dependent insulinotropic polypeptide, another gut hormone involved in blood glucose regulation and energy balance.
It is often grouped with GLP-1 medications, but technically it is a dual GIP and GLP-1 receptor agonist. That distinction matters because tirzepatide’s effects should not automatically be attributed to every medication in the GLP-1 class.
These medications may influence health through several overlapping pathways:
- reducing food intake and body weight
- improving blood glucose control
- reducing visceral fat around internal organs
- lowering blood pressure in some people
- reducing mechanical strain on the heart and airways
- potentially reducing liver fat
- changing inflammatory and metabolic signaling
- possibly producing direct tissue effects, depending on the organ and condition being studied
The difficult part is separating these effects. In many studies, weight loss, improved blood glucose, and organ-specific changes happen at the same time.
Why are researchers finding effects in so many different organs?
At first, it may seem surprising that one group of medications is being studied for the heart, kidneys, liver, sleep, reproductive health, and even addiction.
The explanation is that obesity, insulin resistance, and metabolic dysfunction do not affect only one organ.
They influence many systems at once.
Visceral fat, the fat stored around the internal organs, is metabolically active. It releases inflammatory signals, contributes to insulin resistance, and is strongly associated with cardiovascular and liver disease.
Insulin resistance affects the pancreas, liver, muscles, blood vessels, ovaries, and brain. Poor glucose control can damage small blood vessels in the kidneys and eyes. Excess body weight may increase mechanical pressure on the heart, joints, and airways. Chronic inflammation can influence tissue function throughout the body.
This is why improving the underlying metabolic environment may lead to changes across several organs at once.
The effect may come from weight loss, improved blood glucose, reduced visceral fat, lower inflammation, direct receptor activity, or a combination of these mechanisms.
This is also why “benefits beyond weight loss” should not automatically be interpreted as direct organ repair.
Sometimes the organ improves because the broader metabolic conditions surrounding it have improved.
The evidence is not equal across every condition
A useful way to understand the current research is to think of it as an evidence ladder.
|
Evidence level |
Area |
What we currently know |
|---|---|---|
|
Strong clinical evidence in defined populations |
Cardiovascular disease, diabetic kidney disease, MASH, obstructive sleep apnea |
Large trials show meaningful benefits |
|
Strong but population-specific evidence |
Obesity-related heart failure with preserved ejection fraction |
In adults with obesity-related HFpEF, semaglutide improves symptoms, physical function, and quality of life, while tirzepatide has also demonstrated a reduction in worsening heart-failure events and cardiovascular death in a phase 3 trial. |
|
Promising but investigational |
PCOS, alcohol use disorder |
Early studies suggest benefit, but more research is needed |
|
Not established or disappointing in phase 3 trials |
Alzheimer’s disease, Parkinson’s disease, endometriosis, “anti-aging” |
Interesting biology has not translated into proven clinical benefit |
1. Cardiovascular protection is one of the clearest benefits
Some of the strongest evidence beyond weight loss currently comes from cardiovascular disease.
The SELECT trial included more than 17,000 adults who had established cardiovascular disease and overweight or obesity, but not diabetes. Participants received semaglutide or placebo alongside usual cardiovascular care.
Major cardiovascular events, including heart attack, stroke, or cardiovascular death, occurred in 6.5% of participants receiving semaglutide, compared with 8.0% receiving placebo.
That represents approximately a 20% relative risk reduction and an absolute difference of 1.5 percentage points.
Both numbers matter.
Relative risk describes the proportional change between groups. Absolute risk shows the actual difference in event rates within the study population.
Because of these findings, the FDA approved Wegovy in 2024 to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and overweight or obesity.
However, this does not mean semaglutide prevents heart attacks in every healthy adult. The study involved people who were already at elevated cardiovascular risk.
Why might the heart benefit?
Losing weight likely plays an important role. Visceral fat contributes to inflammation, insulin resistance, abnormal lipid metabolism, and cardiovascular risk. Reducing this fat may influence much more than body weight alone.
Improvements in blood pressure, blood glucose, inflammation, visceral fat, and cholesterol may all contribute.
Researchers are still determining how much of the protection comes from direct GLP-1 receptor effects and how much comes from broader metabolic improvement.
2. Kidney protection is now supported by a major trial
The FLOW trial studied more than 3,500 adults with type 2 diabetes and chronic kidney disease.
Semaglutide reduced the risk of kidney disease progression, kidney failure, or death from kidney or cardiovascular causes by 24% compared with placebo. It also reduced cardiovascular events and all-cause mortality.
These findings led to an expanded FDA indication for Ozempic in adults with type 2 diabetes and chronic kidney disease.
The kidney benefit likely comes from several directions.
Better glucose control may help protect the small blood vessels inside the kidneys. Lower blood pressure and body weight may reduce strain on kidney function. There may also be effects on inflammation, kidney blood flow, and albumin leakage into the urine.
However, this evidence is specific to people with both type 2 diabetes and chronic kidney disease.
It does not mean semaglutide has been proven to protect the kidneys of every healthy person or replace established kidney treatments.
3. Liver disease has moved from “promising” to approved
MASH (previously known as non-alcoholic steatohepatitis (NASH)) or metabolic dysfunction-associated steatohepatitis is a serious form of fatty liver disease involving liver fat, inflammation, and scarring.
In 2025, the FDA granted accelerated approval to semaglutide for adults with MASH and moderate-to-advanced liver fibrosis.
In a phase 3 trial after 72 weeks:
- 63% of semaglutide users experienced MASH resolution without worsening fibrosis, compared with 34% receiving placebo.
- 37% experienced fibrosis improvement without worsening MASH, compared with 22% receiving placebo.
These are meaningful tissue-level improvements.
However, the approval was accelerated because the results were based on liver biopsy findings rather than final clinical outcomes such as liver failure, transplantation, or death.
The trial is continuing to determine whether these changes translate into fewer serious liver complications.
The mechanism is probably mixed.
Weight loss can reduce liver fat and insulin resistance. Better blood glucose and triglyceride control may also help. Direct effects on inflammation and liver signaling are possible, but the contribution of each pathway is still being studied.
4. Sleep apnea can improve, mostly through weight reduction
Obstructive sleep apnea occurs when the upper airway repeatedly narrows or closes during sleep.
In 2024, tirzepatide became the first FDA-approved medication for moderate-to-severe obstructive sleep apnea in adults with obesity.
Two 52-week trials involving 469 adults showed that tirzepatide reduced the apnea-hypopnea index, which measures how often breathing stops or becomes shallow during sleep. More participants also reached remission or mild disease compared with placebo.
This is clinically important, but the mechanism should not be overstated.
The FDA noted that much of the benefit was likely related to weight reduction. Losing fat around the neck, tongue, and upper airway can help reduce airway collapse during sleep.
That does not make the benefit less meaningful.
It simply means we should not assume the medication directly repairs sleep physiology independently of weight loss.
5. Some forms of heart failure may respond
Heart failure with preserved ejection fraction, or HFpEF, is a condition in which the heart can still squeeze relatively normally but becomes stiff and does not fill efficiently.
People with HFpEF may experience breathlessness, fatigue, reduced exercise capacity, and fluid retention.
The STEP-HFpEF trial found that semaglutide improved symptoms, physical function, walking ability, and body weight in adults with obesity-related HFpEF.
After 52 weeks, symptom improvements were approximately twice as large as those seen with placebo.
This does not mean GLP-1 medications treat every type of heart failure.
The evidence is strongest for HFpEF that is closely linked with obesity and metabolic dysfunction.
Benefits may come from weight loss, reduced blood volume, improved mobility, lower inflammation, and reduced mechanical strain on the heart.
6. Alcohol cravings look promising, but the trial was small
One of the most interesting emerging areas involves addictive behavior.
GLP-1 signaling interacts with brain regions involved in motivation, reinforcement, and reward. This has led researchers to ask whether medications that reduce food reward may also reduce cravings for alcohol or other substances.
A 2025 trial involving 48 adults with alcohol use disorder who were not actively seeking treatment found that low-dose semaglutide reduced alcohol consumption and cravings over nine weeks compared with placebo.
Nearly 40% of participants receiving semaglutide reported no heavy-drinking days during the final month, compared with 20% receiving placebo.
The findings are interesting, but not definitive.
The study was small, short, and not designed to prove long-term recovery, relapse prevention, or safety.
Semaglutide is not currently approved for alcohol use disorder.
This type of result calls for larger trials, not viral conclusions.
7. PMOS, formerly known as PCOS, may benefit metabolically, but GLP-1 medications are not fertility treatments
Polyendocrine metabolic ovarian syndrome, or PMOS, is the new name for the condition previously known as polycystic ovary syndrome, or PCOS.
The updated name better reflects the fact that this is a multi-system endocrine and metabolic condition, not simply a problem involving ovarian “cysts.” Many people with the condition do not have ovarian cysts at all. PMOS may involve insulin resistance, higher androgen activity, irregular ovulation, changes in weight regulation, and broader metabolic and reproductive effects.
Because most published studies still use the older term PCOS, that name will continue to appear when discussing the current evidence.
Insulin resistance can stimulate ovarian androgen production. Therefore, improving insulin sensitivity and reducing excess weight may help some features of PMOS.
A 2025 meta-analysis of 13 trials found that GLP-1 receptor agonists reduced body weight, BMI, waist circumference, and insulin resistance in women diagnosed with PCOS.
Average weight loss was approximately 3.6 kilograms compared with metformin or placebo, although study results varied.
Hormonal outcomes were less consistent. Testosterone and several other reproductive markers did not improve reliably across the full analysis. Gastrointestinal side effects were also more common.
Many of the improvements seen in PMOS may therefore be secondary to weight loss and improved insulin sensitivity, rather than direct effects on the ovaries.
The most accurate current framing is:
GLP-1 medications may help the metabolic side of PMOS, particularly in women with overweight, obesity, or insulin resistance.
They are not established fertility treatments.
Evidence in people with PMOS who do not have overweight or obesity remains limited, and these medications should not be used during pregnancy. Anyone planning pregnancy needs individualized guidance about when treatment should be stopped.
For endometriosis, the evidence is even earlier. The biological mechanisms may be interesting, but robust human trials are not yet available.
8. The brain story shows that promising biology can still fail
Early animal studies and observational research suggested that GLP-1 medications might reduce neuroinflammation, improve brain glucose use, or protect neurons.
But large clinical trials have been disappointing.
The EVOKE and EVOKE+ phase 3 studies tested oral semaglutide in more than 3,800 adults with early Alzheimer’s disease.
The medication improved some biomarkers, but it did not slow clinical disease progression compared with placebo.
Parkinson’s disease produced a similar result.
A 2025 phase 3 trial of once-weekly exenatide for 96 weeks found no evidence that the medication slowed disease progression or meaningfully improved symptoms.
This does not mean every future brain-focused GLP-1 strategy will fail. Different drugs, doses, disease stages, or combinations may produce different results.
But it shows why biomarkers, animal studies, and observational associations are not enough.
A medication must improve outcomes that matter to patients.
What about “anti-aging” claims?
GLP-1 medications are sometimes described online as possible “anti-aging” drugs because they may improve several risk factors associated with aging at the same time.
These can include:
- excess body weight
- insulin resistance
- inflammation
- cardiovascular risk
- liver fat
- sleep apnea
Improving several age-related risk factors may support healthier aging.
However, that does not automatically mean the medication slows biological aging itself, extends lifespan in humans, or acts as a general longevity treatment.
At present, “anti-aging” is a much stronger claim than the evidence supports.
“Beyond weight loss” does not always mean “independent of weight loss”
This may be the most important point in the entire article.
GLP-1 medications support weight loss mainly by reducing appetite, lowering food intake, and slowing gastric emptying, which can help fullness last longer.
When someone loses a substantial amount of weight, several things may change at once:
- visceral fat decreases
- insulin sensitivity improves
- blood pressure may fall
- liver fat declines
- sleep apnea may improve
- physical activity becomes easier
- inflammatory signals may decrease
- strain on the heart and joints may lessen
These are real health benefits.
But it can be difficult to determine whether GLP-1 medications act directly on each organ, or whether the organs improve because the body’s overall metabolic environment has changed.
The answer is often a combination of both.
That is not a weakness.
It is simply more accurate than saying the medication “heals” every organ directly.
Benefits do not erase the tradeoffs
GLP-1 medications are prescription drugs, not wellness supplements.
The most common side effects are gastrointestinal, which is not surprising when one of the medication’s main actions is slowing stomach emptying.
Common effects include:
- nausea
- vomiting
- diarrhea
- constipation
- reflux
- abdominal discomfort
Product labels also include warnings involving diabetic retinopathy in certain patients and less common but serious risks such as pancreatitis, gallbladder disease, and dehydration-related kidney injury.
Injection-site and allergic reactions may occur with injectable medications. Contraindications and warnings also vary by drug.
Nutrition deserves more attention than it often receives.
Some people also experience reduced enjoyment of food or early fullness, making meal quality even more important. It can become difficult to consume enough:
- protein
- fluid
- fiber
- vitamins and minerals
- total energy
Substantial weight loss almost always includes some lean tissue as well as body fat.
This is not unique to GLP-1 medications. Similar changes can occur after bariatric surgery, very-low-calorie diets, and other forms of rapid or substantial weight loss.
Resistance training, adequate protein intake, hydration, gradual dose adjustment, enough sleep, and ongoing clinical monitoring may help protect muscle strength and nutritional status.
The goal is not to eat as little as possible.
It is to receive the benefits of treatment while preserving muscle, physical function, digestion, and long-term diet quality.
Weight regain
Current evidence also suggests that many people regain a substantial amount of lost weight after discontinuing GLP-1 medications. This does not necessarily mean the medications "failed." Obesity is a chronic disease, and many long-term treatments require ongoing therapy.
Bottom line
GLP-1 medications do more than help people eat less.
In defined patient groups, strong trials now show benefits involving cardiovascular events, diabetic kidney disease, MASH, obstructive sleep apnea, and obesity-related heart failure symptoms.
Other areas, including PCOS and alcohol use disorder, appear promising but are not yet fully established.
And some of the most exciting early theories, particularly those involving Alzheimer’s and Parkinson’s disease, have not translated into successful phase 3 outcomes.
That is not a failure.
It is how science moves forward.
We begin with a mechanism. We test it in people. We measure outcomes that actually matter. Then we separate what is proven from what is merely possible.
Perhaps the most important lesson is not simply that GLP-1 medications may affect many organs.
It is that metabolism connects many organs.
Improve the underlying metabolic environment, and several systems may improve together.
That is why the most important discoveries are not about finding a miracle drug.
They are about better understanding how interconnected the human body really is.
GLP-1 medications may become increasingly important tools across several areas of medicine.
But they are not universal organ-protection drugs, anti-aging treatments, or substitutes for individualized medical and nutritional care.
The most accurate conclusion is also the most useful:
Their benefits extend beyond weight loss, but how far they extend depends on the medication, the condition, the patient population, and the quality of the evidence.
Like every powerful therapy, their value depends on matching the right treatment to the right patient at the right time.
References
- Cummings, J. L., Atri, A., Feldman, H. H., et al. (2025). EVOKE and EVOKE+: Design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimer’s Research & Therapy, 17, 14. https://doi.org/10.1186/s13195-024-01666-7
- Hendershot, C. S., Bremmer, M. P., Paladino, M. B., et al. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2024.4789
- Issa, D., Newsome, P. N., Kliers, I., Østergaard, L., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V. (2025). Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. The New England Journal of Medicine.
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., et al. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. The New England Journal of Medicine, 389(12), 1069–1084. https://doi.org/10.1056/NEJMoa2306963
- Lin, S., Deng, Y., Huang, J., et al. (2025). Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in women with PCOS: A meta-analysis of randomized controlled trials. Scientific Reports, 15, 16512. https://doi.org/10.1038/s41598-025-99622-4
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
- Malhotra, A., Grunstein, R. R., Fietze, I., et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. The New England Journal of Medicine, 391(13), 1193–1205. https://doi.org/10.1056/NEJMoa2404881
- Perkovic, V., Tuttle, K. R., Rossing, P., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. The New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/NEJMoa2403347
- U.S. Food and Drug Administration. (2024). FDA approves first medication for obstructive sleep apnea.
- U.S. Food and Drug Administration. (2024). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight.
- U.S. Food and Drug Administration. (2025). FDA approves treatment for serious liver disease known as MASH.
- Vijiaratnam, N., Girges, C., Auld, G., et al. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomized, placebo-controlled trial. The Lancet, 405(10479), 627–636. https://doi.org/10.1016/S0140-6736(24)02808-3
Frequently Asked Questions about GLP-1 Medications
What are GLP-1 agonists and how do they work?
GLP-1 agonists are medications that mimic the naturally occurring hormone glucagon-like peptide-1 (GLP-1) produced by the body. They help regulate blood sugar by stimulating insulin secretion when glucose levels are high, reducing glucagon release, slowing gastric emptying, and promoting satiety. This leads to improved glycemic control and weight loss.
Are GLP-1 medications FDA-approved for diabetes and weight loss?
Yes. The FDA first approved the GLP-1 agonist exenatide in 2005 for type 2 diabetes treatment. Semaglutide and high-dose liraglutide are FDA-approved for obesity management. Tirzepatide, a dual GLP-1/GIP receptor agonist, is also approved for type 2 diabetes and obesity.
How are GLP-1 medications administered?
Most GLP-1 agonists are given via subcutaneous injection, either daily or weekly, depending on the drug. Semaglutide is available in both weekly injectable and daily oral forms. Proper injection technique and rotating injection sites help reduce injection site reactions.
What are common side effects of GLP-1 medications?
Gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and upset stomach are common, especially when starting treatment. Injection site reactions and hypersensitivity reactions may also occur. Real-world discontinuation is common, but rates vary considerably by medication, indication, insurance coverage, and study population. Adverse effects contribute, but cost, coverage restrictions, supply problems, and access barriers are also important reasons for stopping treatment.
Can GLP-1 medications help protect the heart and kidneys?
Strong clinical trials show that GLP-1 agonists improve cardiovascular outcomes and reduce progression of diabetic kidney disease in patients with type 2 diabetes. These benefits are partly due to improved blood glucose control, weight loss, and blood pressure reduction.
Are GLP-1 medications safe for people with a family history of medullary thyroid cancer?
Several GLP-1-based medications, including semaglutide and tirzepatide products, carry a boxed warning and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Warnings and contraindications vary by medication, and the human relevance of thyroid C-cell tumors observed in rodents remains uncertain. Always inform your healthcare provider about your medical and family history before starting therapy.
How do GLP-1 medications affect weight loss?
GLP-1 agonists reduce appetite and slow gastric emptying, leading to decreased food intake and significant weight loss. For example, patients using semaglutide (Wegovy) have lost about 15% of their body weight over 1.5 years on average.
What should I do if I experience severe side effects?
If you experience severe abdominal pain, signs of pancreatitis, acute kidney injury symptoms, or hypersensitivity reactions, contact your healthcare provider immediately for medical evaluation and guidance.
How does insurance coverage affect access to GLP-1 medications?
Insurance coverage varies widely. In KFF’s 2025 employer survey, coverage varied substantially by employer size and survey definition. Approximately one in five firms with 200 or more employees reported covering GLP-1 medications for weight loss, while coverage was higher among the largest employers. A temporary Medicare GLP-1 Bridge program began on July 1, 2026, offering selected medications at reduced cost to eligible Part D beneficiaries who meet the program’s clinical and authorization criteria.
Can children or adolescents take GLP-1 medications?
Semaglutide, under the brand name Wegovy, is FDA-approved for chronic weight management in adolescents aged 12 and older. As of July 2026, tirzepatide remains approved for adult indications in the United States, although pediatric clinical trials are underway. Use in younger children is off-label and requires careful medical evaluation.
Are GLP-1 medications effective for conditions beyond diabetes and obesity?
Emerging evidence supports benefits for metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, and obesity-related heart failure. Early studies also suggest potential in alcohol use disorder and PCOS, but more research is needed.
What lifestyle changes should accompany GLP-1 treatment?
GLP-1 medications work best alongside healthy habits such as dietary changes, regular physical activity, adequate hydration, and sufficient protein intake to support muscle preservation and overall health.